Roll Call: IL HB5405 | 2023-2024 | 103rd General Assembly
For additional roll call votes on Illinois HB5405 please see the Vote List
Bill Title: Amends the Department of Public Health Powers and Duties Law of the Civil Administrative Code of Illinois. Sets forth requirements for any State entity or hospital that receives funding from the National Institutes of Health to conduct clinical trials of drugs or medical devices. Provides that the Department of Public Health, in consultation with relevant research organizations, shall analyze and provide recommendations on: (i) the demographic groups and populations that are currently represented and underrepresented in clinical trials in the State, including representation of groups based on their geographic location; (ii) the barriers that prevent persons who are members of underrepresented demographic groups from participating in clinical trials in the State, including barriers related to transportation; and (iii) approaches for how clinical trials can successfully partner with others to provide outreach to underrepresented communities. Provides that the Department shall report to the General Assembly on the results of the study by July 1, 2025. Sets forth definitions of underrepresented community and underrepresented demographic group. Provides that the Department shall review guidance published by the United States Food and Drug Administration and use existing infrastructure to encourage participation in clinical trials of drugs and medical devices by persons who are members of underrepresented demographic groups. Authorizes the Department to apply for any grants related to the encouragement of underrepresented demographic groups related to the United Food and Drug Administration's guidance.
Spectrum: Partisan Bill (Democrat 17-0)
Status: (Passed) 2024-08-09 - Public Act . . . . . . . . . 103-0860 [HB5405 Detail]
Text: Latest bill text (Chaptered) [HTML]
Bill Title: Amends the Department of Public Health Powers and Duties Law of the Civil Administrative Code of Illinois. Sets forth requirements for any State entity or hospital that receives funding from the National Institutes of Health to conduct clinical trials of drugs or medical devices. Provides that the Department of Public Health, in consultation with relevant research organizations, shall analyze and provide recommendations on: (i) the demographic groups and populations that are currently represented and underrepresented in clinical trials in the State, including representation of groups based on their geographic location; (ii) the barriers that prevent persons who are members of underrepresented demographic groups from participating in clinical trials in the State, including barriers related to transportation; and (iii) approaches for how clinical trials can successfully partner with others to provide outreach to underrepresented communities. Provides that the Department shall report to the General Assembly on the results of the study by July 1, 2025. Sets forth definitions of underrepresented community and underrepresented demographic group. Provides that the Department shall review guidance published by the United States Food and Drug Administration and use existing infrastructure to encourage participation in clinical trials of drugs and medical devices by persons who are members of underrepresented demographic groups. Authorizes the Department to apply for any grants related to the encouragement of underrepresented demographic groups related to the United Food and Drug Administration's guidance.
Spectrum: Partisan Bill (Democrat 17-0)
Status: (Passed) 2024-08-09 - Public Act . . . . . . . . . 103-0860 [HB5405 Detail]
Text: Latest bill text (Chaptered) [HTML]
Vote: Third Reading in Senate
| Vote | Tally | Democrat | Republican |
|---|---|---|---|
| Yea | 57 | 40 | 17 |
| Nay | 1 | - | 1 |
| Not Voting | 1 | - | 1 |
| Absent | - | - | - |
| TOTAL | 59 | 40 | 19 |
